DOCSLIB.ORG

Gene Expression Signatures and Response to Imatinib Mesylate in Gastrointestinal Stromal Tumor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gene Expression Signatures and Response to Imatinib Mesylate in Gastrointestinal Stromal Tumor Published OnlineFirst August 11, 2009; DOI: 10.1158/1535-7163.MCT-09-0193 2172 Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor Lori Rink,1 Yuliya Skorobogatko,1 on Statistical Analysis of Microarrays [False Discovery Rate Andrew V. Kossenkov,1 Martin G. Belinsky,1 (FDR), 10%], 38 genes were expressed at significantly low- Thomas Pajak,2 Michael C. Heinrich,3 er levels in the pretreatment biopsy samples from tumors Charles D. Blanke,4 Margaret von Mehren,1 that significantly responded to 8 to 12 weeks of imatinib Michael F. Ochs,5 Burton Eisenberg,6 mesylate, that is, >25% tumor reduction. Eighteen of these genes encoded Krüppel-associated box (KRAB) domain con- and Andrew K. Godwin1 taining zinc finger (ZNF) transcriptional repressors. Impor- 1Department of Medical Oncology, Fox Chase Cancer Center, tantly, 10 KRAB-ZNF genes mapped to a single locus on and 2Radiation Therapy Oncology Group, Philadelphia, chromosome 19p, and a subset predicted likely response Pennsylvania; 3Oregon Health and Science University, Portland, – 4 to imatinib mesylate based therapy in a naïve panel of GIST. Oregon; University of British Columbia and the British Columbia Furthermore, we found that modifying expression of genes Cancer Agency, Vancouver, British Columbia, Canada; 5The Sidney Kimmel Cancer Center, Johns Hopkins University, within this predictive signature can enhance the sensitivity Baltimore, Maryland; and 6Norris Cotton Cancer Center, of GIST cells to imatinib mesylate. Using clinical pretreat- Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire ment biopsy samples from a prospective neoadjuvant phase II trial, we have identified a gene signature that includes KRAB-ZNF 91 subfamily members that may be both predic- Abstract tive of and functionally associated with likely response to Despite initial efficacy of imatinib mesylate in most gastro- short-term imatinib mesylate treatment. [Mol Cancer Ther intestinal stromal tumor (GIST) patients, many experience 2009;8(8):2172–82] primary/secondary drug resistance. Therefore, clinical man- agement of GIST may benefit from further molecular char- acterization of tumors before and after imatinib mesylate Introduction treatment. As part of a recent phase II trial of neoadju- Gastrointestinal stromal tumors (GIST) are the most com- vant/adjuvant imatinib mesylate treatment for advanced mon mesenchymal tumors of the digestive tract, with be- primary and recurrent operable GISTs (Radiation Therapy tween 3,300 to 6,000 new cases diagnosed each year in the Oncology Group S0132), gene expression profiling using ol- United States (1). The most common primary sites for these – igonucleotide microarrays was done on tumor samples ob- neoplasms are the stomach (60 70%; refs. 2, 3), followed by – tained before and after imatinib mesylate therapy. Patients the small intestine (25 35%; refs. 4, 5), and, to a much lesser were classified according to changes in tumor size degree, the colon and rectum (10%; ref. 6). GISTs have also after treatment based on computed tomography scan mea- been observed in the mesentery, omentum, esophagus, and surements. Gene profiling data were evaluated with Sta- the peritoneum (2, 7). GISTs occur most frequently in pa- tistical Analysis of Microarrays to identify differentially tients older than 50 years, with a median age of presentation expressed genes (in pretreatment GIST samples). Based of 58 years; however, GISTs have also been observed in the pediatric population (8). These tumors contain smooth mus- cle and neural elements, as described originally by Mazur and Clark in 1983, and are thought to arise from the inter- Received 12/3/08; revised 5/4/09; accepted 6/3/09; published OnlineFirst 8/11/09. stitial cells of Cajal (9, 10). GISTs express and are clinically Grant support: NIH grants (CA106588 and a supplement from the diagnosed by immunohistochemical (IHC) staining of the Radiation Therapy Oncology Group to U10 CA21661; A.K. Godwin), 145-kDa transmembrane glycoprotein, KIT, by the CD117 LM009382 (M.F. Ochs), an award by the Fox Chase Cancer Center antibody. Most (∼70%) GISTs possess gain-of-function mu- Translational Research Committee as part of the Fox Chase Cancer Center core grant (P30 CA006927; M. vonMehren and A.K. Godwin), and the tations in c-KIT in either exons 9, 11, 13, or 17, causing con- NIH Training Grant (Institutional National Research Service Award) stitutive activation of the kinase receptor, whereas smaller Appointment (CA009035-31; L. Rink). subsets of GISTs possess either gain-of-function mutations The costs of publication of this article were defrayed in part by the PDGFRA ∼ payment of page charges. This article must therefore be hereby marked in (exons 12, 14, or 18; 10%) or no mutations advertisement in accordance with 18 U.S.C. Section 1734 solely to in either KIT or PDGFRA and are therefore referred to as indicate this fact. wild-type GISTs (∼15–20%; refs. 11–14). The primary treat- Note: L. Rink and Y. Skorobogatko contributed equally to this work. ment for GIST is surgical resection, which is often not cura- Current address for A.V. Kossenkov: Wistar Institute, Philadelphia, PA. tive in high risk GIST because of a high incidence of Requests for reprints: Andrew K. Godwin, Department of Medical reoccurrence (15, 16). Since 2002, imatinib mesylate, an oral Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-2756; Fax: 215-728-2741. 2-phenylaminopyrimidine derivative that works as a selec- E-mail: [email protected] tive inhibitor against mutant forms of type III tyrosine Copyright © 2009 American Association for Cancer Research. kinases, such as KIT, PDGFRA, and BCR/ABL, has become doi:10.1158/1535-7163.MCT-09-0193 a standard treatment for patients with metastatic and/or Mol Cancer Ther 2009;8(8). August 2009 Downloaded from mct.aacrjournals.org on September 28, 2021. © 2009 American Association for Cancer Research. Published OnlineFirst August 11, 2009; DOI: 10.1158/1535-7163.MCT-09-0193 Molecular Cancer Therapeutics 2173 unresectable GIST, with objective responses or stable Therapy Oncology Group S0132 trial from 18 institutions. disease obtained in >80% of patients (17, 18). Response to Patients' GIST samples were screened for CD117 (KIT) pos- imatinib mesylate has been correlated to the genotype of a itivity by standard IHC before participation in the clinical given tumor (14). GIST patients with exon 11 KIT mutations trial. Patients were required to have adequate hematologic, have the best response and disease-free survival, whereas renal, and hepatic function, as well as measurable disease other KIT mutation types and wild-type GIST have worse for response evaluation. All patients signed informed con- prognoses. Despite the efficacy of imatinib mesylate, some sent following Institutional Review Board approval for this patients experience primary and/or secondary resistance to study and were consented to provide baseline biopsies and the drug. 18F-fluorodeoxyglucose-positron emission tomog- operative tissue. raphy can be used to rapidly assess tumor response to im- Collection of Samples atinib mesylate (19); however, there are cases in which GISTs Tumor samples were obtained from pre–imatinib mesylate do not take up significant amounts of the glucose precursor, core needle biopsies (pretreatment samples) and from the and therefore, this scanning method is of questionable value surgical specimen obtained at the time of resection following in evaluating response in this group of patients. Strategies for neoadjuvant/preoperative imatinib mesylate (posttreatment treatment of progressive disease can include imatinib mesy- samples). A total of 48 pre- and 34 post-imatinib-treated sam- late dose escalation (20), imatinib mesylate in combination ples were collected and banked. All patients received imati- with surgery, and alternative KIT/PDGFRA inhibitors, in- nib mesylate at 600 mg daily by mouth, which was continued cluding sunitinib (21). There are also options to participate daily until the day of surgery, with dose modifications for in clinical trials evaluating nilotinib (22), dasatinib (23), and protocol-defined toxicities. Fresh-frozen pre- and posttreat- HSP90 inhibitors (24). What may eventually prove to be the ment GIST samples were collected from all participating in- most effective paradigm in the clinical management of GIST stitutions and shipped to the Radiation Therapy Oncology is the development of individualized treatment approaches Group tissue bank before evaluation. based on KIT and PDGFRA mutational status and/or predic- RNA Isolation tive gene signatures of drug response. Ideally, in the future, Total RNA was isolated from all available pre- and post- patients may be preselected for treatment with imatinib me- frozen tissue samples using TRIzol reagent, according to the sylate or additional first- and second-line therapies based on protocols provided by the manufacturer (Invitrogen Corp.). these tumor-specific response markers. RNA quantification and quality assessment were done on The question of whether imatinib mesylate can be safe 2100 Bioanalyser (Agilent Technologies). Because of the and effective as a rapid cytoreductive agent if adminis- high variability in tissue collection and handling, storage tered before surgical resection has been evaluated in a re- and shipping procedures among the 18 institutions in- cent novel phase II trial (Radiation Therapy Oncology volved in the study, and the tumor cellularity
Load more

Recommended publications
  • Universidade Estadual De Campinas Instituto De Biologia
    UNIVERSIDADE ESTADUAL DE CAMPINAS INSTITUTO DE BIOLOGIA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA CAMPINAS 2016 1 VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA Dissertação apresentada ao Instituto de Biologia da Universidade Estadual de Campinas como parte dos requisitos exigidos para a obtenção do Título de Mestra em Biologia Funcional e Molecular na área de concentração de Bioquímica. Dissertation presented to the Institute of Biology of the University of Campinas in partial fulfillment of the requirements for the degree of Master in Functional and Molecular Biology, in the area of Biochemistry. ESTE ARQUIVO DIGITAL CORRESPONDE À VERSÃO FINAL DA DISSERTAÇÃO DEFENDIDA PELA ALUNA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA E ORIENTADA PELO DANIEL MARTINS-DE-SOUZA. Orientador: Daniel Martins-de-Souza CAMPINAS 2016 2 Agência(s) de fomento e nº(s) de processo(s): CNPq, 151787/2F2014-0 Ficha catalográfica Universidade Estadual de Campinas Biblioteca do Instituto de Biologia Mara Janaina de Oliveira - CRB 8/6972 Saia-Cereda, Verônica Aparecida Monteiro, 1988- Sa21p O proteoma do corpo caloso da esquizofrenia / Verônica Aparecida Monteiro Saia Cereda. – Campinas, SP : [s.n.], 2016. Orientador: Daniel Martins de Souza. Dissertação (mestrado) – Universidade Estadual de Campinas, Instituto de Biologia. 1. Esquizofrenia. 2. Espectrometria de massas. 3. Corpo caloso.
    [Show full text]
  • Targeted Sequence Capture and Ultra High Throughput Sequencing for Gene Discovery in Inherited Diseases
    Unicentre CH-1015 Lausanne http://serval.unil.ch Year : 2013 Targeted sequence capture and Ultra High Throughput sequencing for gene discovery in inherited diseases Dl GIOIA SILVIO ALESSANDRO Dl GIOIA SILVIO ALESSANDRO, 2013, Targeted sequence capture and Ultra High Throughput sequencing for gene discovery in inherited diseases Originally published at : Thesis, University of Lausanne Posted at the University of Lausanne Open Archive. http://serval.unil.ch Droits d’auteur L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir le consentement préalable de l'auteur et/ou de l’éditeur avant toute utilisation d'une oeuvre ou d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette loi. Nous déclinons toute responsabilité en la matière. Copyright The University of Lausanne expressly draws the attention of users to the fact that all documents published in the SERVAL Archive are protected by copyright in accordance with federal law on copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the author and/or publisher before any use of a work or part of a work for purposes other than personal use within the meaning of LDA (art. 19, para.
    [Show full text]
  • Loci for Human Leukocyte Telomere Length in the Singaporean Chinese Population and Trans-Ethnic Genetic Studies
    ARTICLE https://doi.org/10.1038/s41467-019-10443-2 OPEN Loci for human leukocyte telomere length in the Singaporean Chinese population and trans-ethnic genetic studies Rajkumar Dorajoo 1,14, Xuling Chang2,3,14, Resham Lal Gurung4,14, Zheng Li 1, Ling Wang1, Renwei Wang5, Kenneth B. Beckman 6, Jennifer Adams-Haduch5, Yiamunaa M4, Sylvia Liu4, Wee Yang Meah1, Kar Seng Sim 1, Su Chi Lim4,7,8, Yechiel Friedlander9, Jianjun Liu 1,10, Rob M. van Dam8,10, Jian-Min Yuan 5,11,15, Woon-Puay Koh8,12,15, Chiea Chuen Khor 1,13,15 & Chew-Kiat Heng 2,3,15 1234567890():,; Genetic factors underlying leukocyte telomere length (LTL) may provide insights into telo- mere homeostasis, with direct links to disease susceptibility. Genetic evaluation of 23,096 Singaporean Chinese samples identifies 10 genome-wide loci (P <5×10−8). Several of these contain candidate genes (TINF2, PARP1, TERF1, ATM and POT1) with potential roles in telo- mere biology and DNA repair mechanisms. Meta-analyses with additional 37,505 European individuals reveals six more genome-wide loci, including associations at MPHOSPH6, NKX2-3 and TYMS. We demonstrate that longer LTL associates with protection against respiratory disease mortality [HR = 0.854(0.804–0.906), P = 1.88 × 10−7] in the Singaporean Chinese samples. We further show that the LTL reducing SNP rs7253490 associates with respiratory infections (P = 7.44 × 10−4) although this effect may not be strongly mediated through LTL. Our data expands on the genetic basis of LTL and may indicate on a potential role of LTL in immune competence.
    [Show full text]
  • The Diversity of Zinc-Finger Genes on Human Chromosome 19 Provides
    Cell Death and Differentiation (2014) 21, 381–387 OPEN & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd The diversity of zinc-finger genes on human chromosome 19 provides an evolutionary mechanism for defense against inherited endogenous retroviruses S Lukic*1, J-C Nicolas1 and AJ Levine1 Endogenous retroviruses (ERVs) are remnants of ancient retroviral infections of the germ line that can remain capable of replication within the host genome. In the soma, DNA methylation and repressive chromatin keep the majority of this parasitic DNA transcriptionally silent. However, it is unclear how the host organism adapts to recognize and silence novel invading retroviruses that enter the germ line. Krueppel-Associated Box (KRAB)-associated protein 1 (KAP1) is a transcriptional regulatory factor that drives the epigenetic repression of many different loci in mammalian genomes. Here, we use published experimental data to provide evidence that human KAP1 is recruited to endogenous retroviral DNA by KRAB-containing zinc-finger transcription factors (TFs). Many of these zinc-finger genes exist in clusters associated with human chromosome 19. We demonstrate that these clusters are located at hotspots for copy number variation (CNV), generating a large and continuing diversity of zinc-finger TFs with new generations. These zinc-finger genes possess a wide variety of DNA binding affinities, but their role as transcriptional repressors is conserved. We also perform a computational study of the different ERVs that invaded the human genome during primate evolution. We find candidate zinc-finger repressors that arise in the genome for each ERV family that enters the genomes of primates.
    [Show full text]
  • Identification of MLL-AF9 Related Target Genes and Micrornas Involved in Leukemogenesis
    Identification of MLL-AF9 related target genes and microRNAs involved in leukemogenesis Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) an der Fakultät für Biologie der Ludwig-Maximilians-Universität München Durchgeführt am Forschungszentrum des Dr. von Haunerschen Kinderspitals der Ludwig-Maximilians-Universität München vorgelegt von Katrin Kristina Fleischmann München, 3. Mai 2012 Erstgutachterin: Frau Prof. Dr. Elisabeth Weiss Zweitgutachter: Herr Prof. Dr. Michael Schleicher Sondergutachter: Herr Prof. Dr. Adelbert Roscher Tag der Abgabe: 03.05.2012 Tag der mündlichen Prüfung: 17.09.2012 What is a scientist after all? It is a curious man looking through a keyhole, the keyhole of nature, trying to know what's going on. Jacques Yves Cousteau Preamble and Acknowledgments How to explain the change from evolutionary ecology to tumor biology? After my diploma thesis in evolutionary ecology and a major in ecology, I was facing some skepticism while being interviewed for PhD positions in the biomedical field. What was my motivation to study biology? Why do I continue to feel this strong enthusiasm for this field? For me, it was always the grand question “How does life work?” that drove me and which may interconnect almost every aspect within natural sciences. Only when we strive to get answers to this grand question we may reach an understanding as to what happens in disease. I am profoundly grateful to my dear colleagues Dr. Julia von Frowein, Dr. Thomas Magg and Dr. Uta Fuchs who supported me to become one of their colleagues at the research center of the Dr. von Haunerschen Kinderspital. Since then, innumerable great and inspiring discussions allied us.
    [Show full text]
  • HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant
    Accepted Manuscript HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant William S. Mason, Upkar S. Gill, Samuel Litwin, Yan Zhou, Suraj Peri, Oltin Pop, Michelle L.W. Hong, Sandhia Naik, Alberto Quaglia, Antonio Bertoletti, Patrick T.F. Kennedy PII: S0016-5085(16)34808-9 DOI: 10.1053/j.gastro.2016.07.012 Reference: YGAST 60585 To appear in: Gastroenterology Accepted Date: 7 July 2016 Please cite this article as: Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong MLW, Naik S, Quaglia A, Bertoletti A, Kennedy PTF, HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant, Gastroenterology (2016), doi: 10.1053/ j.gastro.2016.07.012. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT TITLE: HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant SHORT TITLE : Immunopathology in immune tolerant CHB AUTHORS: William S. Mason 1, Upkar S. Gill 2, Samuel Litwin 1, Yan Zhou 1, Suraj Peri 1, Oltin Pop 3, Michelle L.W. Hong 4, Sandhia Naik 5, Alberto Quaglia 3, Antonio Bertoletti 4 & Patrick T.F.
    [Show full text]
  • UC Irvine UC Irvine Electronic Theses and Dissertations
    UC Irvine UC Irvine Electronic Theses and Dissertations Title Investigating developmental and functional deficits in neurodegenerative disease using transcriptomic analyses Permalink https://escholarship.org/uc/item/7wp2w13r Author Lim, Ryan Gar-Lok Publication Date 2016 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, IRVINE Investigating developmental and functional deficits in neurodegenerative disease using transcriptomic analyses DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences by Ryan Gar-Lok Lim Dissertation Committee: Professor Leslie M. Thompson, Chair Assistant Professor Dritan Agalliu Professor Peter Donovan Professor Suzanne Sandmeyer 2016 Introduction, Figure 1.1 © 2014 Macmillan Publishers Limited. Appendix 1 © 2016 Elsevier Ltd. All other materials © 2016 Ryan Gar-Lok Lim DEDICATION This dissertation is dedicated to my parents, sister, and my wife. I love you all very much and could not have accomplished any of this without your love and support. Please take the time to reflect back on all of the moments we’ve shared, and know, that it is because of those moments I have been able to succeed. This accomplishment is as much yours as it is mine. ii TABLE OF CONTENTS Page LIST OF FIGURES vi LIST OF TABLES ix ACKNOWLEDGMENTS x CURRICULUM VITAE xiii ABSTRACT OF THE DISSERTATION xv Introduction Huntington’s disease, the neurovascular unit and the blood-brain
    [Show full text]
  • Characterization of Copy-Number Variations and Possible Candidate Genes in Recurrent Pregnancy Losses
    G C A T T A C G G C A T genes Article Characterization of Copy-Number Variations and Possible Candidate Genes in Recurrent Pregnancy Losses Yan-Ran Sheng 1, Shun-Yu Hou 2, Wen-Ting Hu 1, Chun-Yan Wei 1, Yu-Kai Liu 1, Yu-Yin Liu 1, Lu Jiang 2, Jing-Jing Xiang 2, Xiao-Xi Sun 3,4, Cai-Xia Lei 3,4, Hui-Ling Wang 2,* and Xiao-Yong Zhu 1,4,5,* 1 Laboratory for Reproductive Immunology, Hospital of Obstetrics and Gynecology, Fudan University, Shanghai 200000, China; [email protected] (Y.-R.S.); [email protected] (W.-T.H.); [email protected] (C.-Y.W.); [email protected] (Y.-K.L.); [email protected] (Y.-Y.L.) 2 The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215000, China; [email protected] (S.-Y.H.); [email protected] (L.J.); [email protected] (J.-J.X.) 3 Shanghai Ji Ai Genetics & IVF Institute, Obstetrics & Gynecology Hospital, Fudan University, Shanghai 200000, China; [email protected] (X.-X.S.); [email protected] (C.-X.L.) 4 Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University, Shanghai 200000, China 5 Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200000, China * Correspondence: [email protected] (H.-L.W.); [email protected] (X.-Y.Z.); Tel.: +86-138-0613-2001 (H.-L.W.); +86-021-3318-9900 (X.-Y.Z.) Abstract: It is well established that embryonic chromosomal abnormalities (both in the number of chromosomes and the structure) account for 50% of early pregnancy losses.
    [Show full text]
  • Loci for Human Leukocyte Telomere Length in the Singaporean Chinese Population and Trans-Ethnic Genetic Studies
    ARTICLE https://doi.org/10.1038/s41467-019-10443-2 OPEN Loci for human leukocyte telomere length in the Singaporean Chinese population and trans-ethnic genetic studies Rajkumar Dorajoo 1,14, Xuling Chang2,3,14, Resham Lal Gurung4,14, Zheng Li 1, Ling Wang1, Renwei Wang5, Kenneth B. Beckman 6, Jennifer Adams-Haduch5, Yiamunaa M4, Sylvia Liu4, Wee Yang Meah1, Kar Seng Sim 1, Su Chi Lim4,7,8, Yechiel Friedlander9, Jianjun Liu 1,10, Rob M. van Dam8,10, Jian-Min Yuan 5,11,15, Woon-Puay Koh8,12,15, Chiea Chuen Khor 1,13,15 & Chew-Kiat Heng 2,3,15 1234567890():,; Genetic factors underlying leukocyte telomere length (LTL) may provide insights into telo- mere homeostasis, with direct links to disease susceptibility. Genetic evaluation of 23,096 Singaporean Chinese samples identifies 10 genome-wide loci (P <5×10−8). Several of these contain candidate genes (TINF2, PARP1, TERF1, ATM and POT1) with potential roles in telo- mere biology and DNA repair mechanisms. Meta-analyses with additional 37,505 European individuals reveals six more genome-wide loci, including associations at MPHOSPH6, NKX2-3 and TYMS. We demonstrate that longer LTL associates with protection against respiratory disease mortality [HR = 0.854(0.804–0.906), P = 1.88 × 10−7] in the Singaporean Chinese samples. We further show that the LTL reducing SNP rs7253490 associates with respiratory infections (P = 7.44 × 10−4) although this effect may not be strongly mediated through LTL. Our data expands on the genetic basis of LTL and may indicate on a potential role of LTL in immune competence.
    [Show full text]
  • Comprehensive Identification and Annotation of Nonprotein-Coding
    Comprehensive Identification and Annotation of Non- protein-coding Transcriptomes from Vertebrates Indicates Most ncRNAs are Regulatory Zhipeng Qu A thesis submitted for the degree of Doctor of Philosophy Discipline of Genetics School of Molecular and Biomedical Science The University of Adelaide October 2012 Table of Contents Contents ........................................................................................................................................I Abstract....................................................................................................................................... II Declaration.................................................................................................................................III Acknowledgements .....................................................................................................................V Chapter 1 Introduction................................................................................................................1 Chapter 2 Bovine ncRNAs Are Abundant, Primarily Intergenic, Conserved and Associated with Regulatory Genes .............................................................................................3 Chapter 3 Identification And Comparative Analysis Of ncRNAs In Human, Mouse And Zebrafish Indicate A Conserved Role In Regulation Of Genes Expressed In Brain ............5 Chapter 4 Re-construction and Annotation of Human Protein-coding and Non-coding RNA Co-expression Networks ....................................................................................................7
    [Show full text]
  • SUPPLEMENTARY APPENDIX a B-Cell Receptor-Related Gene Signature Predicts Response to Ibrutinib Treatment in Mantle Cell Lymphoma Cell Lines
    SUPPLEMENTARY APPENDIX A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines Tiziana D'Agaro, 1 Antonella Zucchetto, 1 Filippo Vit, 1,2 Tamara Bittolo, 1 Erika Tissino, 1 Francesca Maria Rossi, 1 Massimo Degan, 1 Francesco Zaja, 3 Pietro Bulian, 1 Michele Dal Bo, 1 Simone Ferrero, 4,5 Marco Ladetto, 4,6 Alberto Zamò, 7 Valter Gattei 1* and Riccardo Bomben 1* *VG and RB equally contributed to this work as senior authors 1Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano; 2Department of Life Science, Univer - sity of Trieste, Trieste; 3Department of Internal Medicine and Haematology, Maggiore General Hospital, University of Trieste, Trieste; 4Department of Molecular Biotechnologies and Health Sciences, Hematology Division 1, University of Torino, Torino; 5Hematology Division 1, AOU “Città della Salute e della Scienza di Torino” University-Hospital, Torino; 6SC Ematologia Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria and 7Department of Oncology, University of Torino, Torino, Italy Correspondence: RICCARDO BOMBEN - [email protected] doi:10.3324/haematol.2018.212811 A B-cell receptor-related gene signature predicts response to ibrutinib treatmeant in Mantle Cell Lymphoma cell lines Supplemental Information: • Supplemental Materials and Methods • Supplemental Figure: o Figure S1. Anti-IgM stimulation and ibrutinib treatment on primary MCL samples. • Supplemental Tables: o Table S1. Differentially expressed genes between BCR low and BCR high MCL cell lines. o Table S2. TP53 mutational status in MCL cell line models 1 MCL cell lines Six different MCL cell line models (Rec-1, Jeko-1, Mino, JVM-2, Granta-519, and Z-138)1 were used for GEP studies and functional experiments.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0053062 A1 BROOKS (43) Pub
    US 20120053062A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0053062 A1 BROOKS (43) Pub. Date: Mar. 1, 2012 (54) DEFINING DAGNOSTIC AND Publication Classification THERAPEUTIC TARGETS OF CONSERVED FREE FLOATING FETAL DNA IN MATERNAL (51) Int. Cl. CIRCULATING BLOOD C40B 20/00 (2006.01) G06F 7/30 (2006.01) (75) Inventor: Andrew BROOKS, New York, NY C40B 40/06 (2006.01) (US) (73) Assignee: Bio Dx, Inc., San Diego, CA (US) (52) U.S. Cl. ......... 506/2:506/16; 707/758; 707/E17.014 (21) Appl. No.: 13/216,992 (22) Filed: Aug. 24, 2011 (57) ABSTRACT Related U.S. Application Data The present invention provides methods and materials useful (60) Provisional application No. 61/376,637, filed on Aug. for detecting cell free fetal DNA as well as markers for fetal 24, 2010. conditions by using biological samples of a maternal host. US 2012/0053062 A1 Mar. 1, 2012 DEFINING DAGNOSTIC AND 0009. In one embodiment, the conserved genomic seg THERAPEUTIC TARGETS OF CONSERVED ment is a genomic segment provided in Table 1. In one FREE FLOATING FETAL DNA IN MATERNAL embodiment, the conserved genomic segment includes any CIRCULATING BLOOD probe identified in Table 1. In another embodiment, the con served genomic segment includes any geneidentified in Table CROSS REFERENCE TO RELATED 1. In yet another embodiment, the conserved genomic seg APPLICATIONS ment is a fragment of a gene identified in Table 1, e.g., a fragment associated with any genotype marker of a gene 0001. This application claims priority to U.S. Provisional identified in Table 1.
    [Show full text]